SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Angelo Andriulli, Alessandra Nardi, Vito Di Marco, Antonio Massimo Ippolito, Caius Gavrila, Alessio Aghemo, Daniele Di Paolo, Giovanni Squadrito, Eleonora Grassi, Vincenza Calvaruso, Maria Rosa Valvano, Giuseppina Brancaccio, Antonio Craxi, Mario Angelico, An a priori prediction model of response to peginterferon plus ribavirin dual therapy in naïve patients with genotype 1 chronic hepatitis C, Digestive and Liver Disease, 2014, 46, 9, 818

    CrossRef

  2. 2
    Joseph Misdraji, Changing indications for liver biopsy: viral hepatitis, Diagnostic Histopathology, 2014, 20, 3, 119

    CrossRef

  3. 3
    Blaire E. Burman, Paul Y. Kwo, Kris V. Kowdley, Comparison of first- and second-wave DAAs for HCV GT1: efficacy, safety, tolerability, and regimen complexity, Hepatology International, 2014, 8, 3, 352

    CrossRef

  4. 4
    E.-I. Pecheur, Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'?, Gut, 2014, 63, 7, 1035

    CrossRef

  5. 5
    Takuji Daito, Koichi Watashi, Ann Sluder, Hirofumi Ohashi, Syo Nakajima, Katyna Borroto-Esoda, Takashi Fujita, Takaji Wakita, Cyclophilin Inhibitors Reduce Phosphorylation of RNA-Dependent Protein Kinase to Restore Expression of IFN-Stimulated Genes in HCV-Infected Cells, Gastroenterology, 2014, 147, 2, 463

    CrossRef

  6. 6
    Makonen Belema, Omar D. Lopez, John A. Bender, Jeffrey L. Romine, Denis R. St. Laurent, David R. Langley, Julie A. Lemm, Donald R. O’Boyle, Jin-Hua Sun, Chunfu Wang, Robert A. Fridell, Nicholas A. Meanwell, Discovery and Development of Hepatitis C Virus NS5A Replication Complex Inhibitors, Journal of Medicinal Chemistry, 2014, 57, 5, 1643

    CrossRef

  7. 7
    Ning-Yu Wang, Wei-Qiong Zuo, Ying Xu, Chao Gao, Xiu-Xiu Zeng, Li-Dan Zhang, Xin-Yu You, Cui-Ting Peng, Yang Shen, Sheng-Yong Yang, Yu-Quan Wei, Luo-Ting Yu, Discovery and structure–activity relationships study of novel thieno[2,3-b]pyridine analogues as hepatitis C virus inhibitors, Bioorganic & Medicinal Chemistry Letters, 2014, 24, 6, 1581

    CrossRef

  8. 8
    Mary C. White, David K. Espey, Judith Swan, Charles L. Wiggins, Christie Eheman, Judith S. Kaur, Disparities in Cancer Mortality and Incidence Among American Indians and Alaska Natives in the United States, American Journal of Public Health, 2014, 104, S3, S377

    CrossRef

  9. 9
    Wen Kang, Hsin-I Tong, Yongtao Sun, Yuanan Lu, Hepatitis C virus infection in patients with HIV-1: epidemiology, natural history and management, Expert Review of Gastroenterology & Hepatology, 2014, 8, 3, 247

    CrossRef

  10. 10
    E. Galmozzi, F. Facchetti, R. Perbellini, A. Aghemo, High-resolution melting assay for genotyping of IFNL4-associated dinucleotide variant rs368234815, Clinical Microbiology and Infection, 2014, 20,
  11. 11
    M. E. Mancuso, S. Linari, A. Aghemo, D. Bartolozzi, E. Santagostino, M. G. Rumi, E. Fognani, M. R. Fasulo, L. Gragnani, R. Bruno, M. Morfini, A. L. Zignego, M. Colombo, Interferon lambda 3 rs12979860 polymorphism in patients with haemophilia and HCV infection: a predictor of spontaneous viral clearance and sustained virological response, Thrombosis and Haemostasis, 2014, 111, 6, 1067

    CrossRef

  12. You have free access to this content12
    Audrey Coilly, Bruno Roche, Jean-Charles Duclos-Vallée, Didier Samuel, Management of HCV transplant patients with triple therapy, Liver International, 2014, 34,
  13. 13
    Hiromi Abe, C. Nelson Hayes, Kazuaki Chayama, New insight into the enhanced effect of pegylated interferon-α, Hepatology, 2014, 60, 4
  14. 14
    Reneé C. Ireton, Michael Gale, Pushing to a cure by harnessing innate immunity against hepatitis C virus, Antiviral Research, 2014, 108, 156

    CrossRef

  15. 15
    J. Ampuero, M. Romero-Gómez, K. R. Reddy, Review article: HCV genotype 3 – the new treatment challenge, Alimentary Pharmacology & Therapeutics, 2014, 39, 7
  16. 16
    Stella De Nicola, Alessio Aghemo, Second wave anti-HCV protease inhibitors: too little too late?, Liver International, 2014, 34, 7
  17. 17
    Alfredo Alberti, Massimo Colombo, Antonio Craxì, Mario Rizzetto, The dilemma for patients with chronic hepatitis C: Treat now or warehouse?, Digestive and Liver Disease, 2014, 46, 1, 27

    CrossRef

  18. 18
    A. Aghemo, M. Colombo, Treatment of patients with dual hepatitis B and C: a step in the right direction, Gut, 2014, 63, 3, 380

    CrossRef

  19. 19
    Daniel Chao, Gregory J. Botwin, Timothy R. Morgan, Update on Recently Approved Treatments for Hepatitis C, Current Treatment Options in Gastroenterology, 2014, 12, 2, 211

    CrossRef

  20. You have free access to this content20
    C. Zingaretti, R. De Francesco, S. Abrignani, Why is it so difficult to develop a hepatitis C virus preventive vaccine?, Clinical Microbiology and Infection, 2014, 20,
  21. 21
    Sonal Kumar, Ira Jacobson, All Oral HCV Therapies of the Future, Current Hepatitis Reports, 2013, 12, 4, 214

    CrossRef

  22. 22
    Daniel Felmlee, Mohamed Hafirassou, Mathieu Lefevre, Thomas Baumert, Catherine Schuster, Hepatitis C Virus, Cholesterol and Lipoproteins — Impact for the Viral Life Cycle and Pathogenesis of Liver Disease, Viruses, 2013, 5, 5, 1292

    CrossRef

  23. 23
    Luis Vida Pérez, La paradoja de la dieta rica en grasa en los inhibidores de proteasa frente a la hepatitis C, Gastroenterología y Hepatología, 2013, 36, 8, 549

    CrossRef

  24. 24
    Daniel J. Felmlee, Fei Xiao, Thomas F. Baumert, Modeling the antiviral activity of ribavirin against hepatitis C virus in cell culture, Hepatology, 2013, 58, 4